Search Legislation

The Health Service Medicines (Control of Prices and Supply of Information) (Amendment) Regulations 2013

 Help about what version

What Version

  • Latest available (Revised)
  • Original (As made)
 Help about opening options

Opening Options

Status:

This is the original version (as it was originally made). This item of legislation is currently only available in its original format.

Amendment of the Health Service Branded Medicines (Control of Prices and Supply of Information) (No.2) Regulations 2008

This section has no associated Explanatory Memorandum

3.—(1) The Health Service Branded Medicines (Control of Prices and Supply of Information) (No.2) Regulations 2008(1) are amended as follows.

(2) In regulation 1 (citation, commencement and interpretation), in paragraph (2)—

(a)for the definition of “presentation” substitute the following definition—

“presentation” means a particular form of a branded health service medicine which may be distinguished from other forms of the medicine by reference to its active ingredients, strength and excipients, pack size, type of packaging, clinical indications, method of administration or formulation for use in clinical practice;, and

(b)omit the definition of “relevant medicine”.

(3) After regulation 1, insert the following regulation—

Expiry

1A.  These Regulations cease to have effect at the end of 31st December 2020..

(4) For regulation 2 (control of prices), substitute the following regulation—

Control of Prices

2.(1) Subject to paragraph (2) to (4) and regulation 4 (low cost presentations), the maximum price which may be charged for the supply of a presentation is the price at which that presentation was on sale for health service purposes on 1st December 2013 less 15 per cent, without regard to any discount or other variation of the price which did not have general application on that date.

(2) In the calculation of maximum price, the percentage reduction set out in paragraph (1) does not apply to a manufacturer or supplier who has, during the most recent complete calendar year, supplied branded health service medicines for health service use in the United Kingdom, from which it derived a sales income of less than £5 million.

(3) This regulation does not apply—

(a)to a manufacturer or supplier to whom a voluntary scheme for the supply of branded health service medicines applies at the time of a supply;

(b)where the presentation has no price on 1st December 2013; or

(c)where the maximum price for the presentation is otherwise determined by any of the following regulations.

(4) Where the amount determined under paragraph (1) results in an amount which includes a fraction of a penny, the maximum price is rounded down to the nearest whole penny..

(5) In regulation 3 (new products), in paragraph (1), for the words from “Where a presentation” to “1st December 2008,” substitute “Where there is no price for a presentation in the United Kingdom on 1st December 2013,”.

(6) For regulation 4 (low cost presentations), substitute the following regulation—

Low cost presentations

4.  If a presentation was on sale for health service purposes on December 1st 2013 for a price of less than £2.00, the maximum price which may be charged for that presentation is the price at which it was on sale for health service purposes on that date, without regard to any discount or other variation of the price which did not have general application on that date..

(7) After regulation 10 (revocation) insert the following regulation—

Review

11.(1) Before the end of the review period, the Secretary of State must—

(a)carry out a review of these Regulations;

(b)set out the conclusions of the review in a report; and

(c)publish the report.

(2) The report must in particular—

(a)set out the objectives intended to be achieved by the regulatory system established by these Regulations;

(b)assess the extent to which those objectives are achieved; and

(c)assess whether those objectives remain appropriate and, if so, the extent to which they could be achieved with a system that imposes less regulation.

(3) “Review period” means the period of seven years beginning on 1st January 2014..

(1)

S.I. 2008/3258; the relevant amending instrument is S.I. 2012/2791.

Back to top

Options/Help

Print Options

Close

Legislation is available in different versions:

Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.

Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.

Close

Opening Options

Different options to open legislation in order to view more content on screen at once

Close

Explanatory Memorandum

Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.

Close

More Resources

Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as enacted version that was used for the print copy
  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • correction slips
  • links to related legislation and further information resources
Close

Impact Assessments

Impact Assessments generally accompany all UK Government interventions of a regulatory nature that affect the private sector, civil society organisations and public services. They apply regardless of whether the regulation originates from a domestic or international source and can accompany primary (Acts etc) and secondary legislation (SIs). An Impact Assessment allows those with an interest in the policy area to understand:

  • Why the government is proposing to intervene;
  • The main options the government is considering, and which one is preferred;
  • How and to what extent new policies may impact on them; and,
  • The estimated costs and benefits of proposed measures.
Close

More Resources

Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as made version that was used for the print copy
  • correction slips

Click 'View More' or select 'More Resources' tab for additional information including:

  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • links to related legislation and further information resources